NCT05402670 is a clinical trial in Gastric Mucosal Manifestations in Patients With Dermatomyositis, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05402670?

NCT05402670 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What condition does NCT05402670 study?

NCT05402670 studies Gastric Mucosal Manifestations in Patients With Dermatomyositis.

Is NCT05402670 still recruiting?

NCT05402670 is currently status unknown. Last updated 2 June 2022.

Last reviewed 2022-06-02 · How we verify

NCT05402670

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gastric Mucosal Changes in Patients With Dermatomyositis

Status unknown Last updated 2 June 2022

What this trial tests

trial in Gastric Mucosal Manifestations in Patients With Dermatomyositis in 150 participants. Status unknown.

Timeline

1 June 2022

Primary endpoint
1 June 2023

1 June 2023

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 June 2022
Primary completion	1 June 2023
Estimated completion	1 June 2023
Sites	1 location across China

Conditions studied

Gastric Mucosal Manifestations in Patients With Dermatomyositis — all drugs for Gastric Mucosal Manifestations in Patients With Dermatomyositis →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 70, any sex, with Gastric Mucosal Manifestations in Patients With Dermatomyositis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are a large number of reports in the literature that patients with dermatomyositis often have various malignant tumors, and reports of gastric cancer are not rare. At present, the widely recognized gastric cancer occurrence patterns are: normal gastric mucosa-chronic superficial gastritis-chronic atrophic gastritis-intestinal metaplasia-dysplasia-gastric cancer, so the research about the gastric mucosal performance of patients with dermatomyositis is clinically meaningful

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05402670 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 2 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05402670.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing